[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"lung-cancers\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:lung-cancers":31},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,22,0,[8,61,85,107,138,168,194,234,271,300,323,357,384,408,431,456,478,500,522,545,593,627],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":26,"conditions":27,"keywords":36,"overallStatus":48,"whyStopped":4,"lastUpdateSubmitDate":49,"lastUpdatePostDateStruct":50,"startDateStruct":53,"completionDateStruct":55,"leadSponsor":57,"locationsCount":60},"100595891","phase-1-aventine-1-study-of-avzo-1418-as-a-single-agent-and-in-combination-therapy-in-patients-with-locally-advanced-or-metastatic-solid-tumors-avzo-1418-1001-100595891",false,"NCT07038343","AVENTINE-1: Study of AVZO-1418 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Solid Tumors (AVZO-1418-1001)","A Phase 1\u002F2, First-in-human Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of AVZO-1418 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Solid Tumors","Key Inclusion Criteria\n\n* Patient must be an adult, between 18 and 75 years of age with an Eastern Cooperative Oncology Group (ECOG) Performance Status of ≤ 1 and a life expectancy of \\> 3 months.\n* Patients with histologically or cytologically confirmed locally advanced\u002Fmetastatic malignancies for tumor types of preferred indications:\n\n  o Locally advanced or metastatic epithelial solid tumors (as specified in the protocol).\n* Measurable disease as assessed by Investigator using RECIST v1.1.\n* Agree to provide molecular test report results to confirm eligibility and archival tumor samples and\u002For fresh biopsy, as applicable.\n* Other protocol-defined Inclusion criteria apply.\n\nKey Exclusion Criteria\n\n* Uncontrolled hypertension.\n* Patients with active central nervous system (CNS) metastases are not eligible. Patients with asymptomatic and treated brain metastases may participate if they are radiologically stable for at least 4 weeks prior to the first dose of this study and do not require steroid treatment. Patients with suspected or confirmed leptomeningeal disease are not eligible, even if treated.\n* History of drug-induced interstitial lung disease (ILD).\n* History of any serious cardiovascular condition.\n* Infection requiring IV antibiotics, antivirals, or antifungals within 2 weeks prior to first dose.\n* History of a solid organ transplant.\n* Other protocol-defined Exclusion criteria apply.","ALL","18 Years","75 Years",{"count":20,"type":21},480,"ESTIMATED","INTERVENTIONAL",[24,25],"PHASE1","PHASE2","This study, the first clinical trial of AVZO-1418, aims to determine the safety, tolerability, pharmacokinetics, pharmacodynamics, maximum tolerated dose, and antitumor activity of AVZO-1418 when administered intravenously as a monotherapy and potentially in combination therapy to patients with locally advanced or metastatic epithelial solid tumors.",[28,29,30,31,32,33,34,35],"Solid Tumor Cancer","Locally Advanced","Metastatic Solid Tumors","Lung Cancers","Epithelial Tumor","Biliary Tract Cancer (BTC)","Urothelial Cancer","Nasopharyngeal Cancers",[37,38,29,39,40,41,34,42,43,44,45,46,47],"Solid Tumors","Metastatic","Lung Cancer","Epithelial Solid Tumors","Biliary Tract Cancer","SCLC","HER3","EGFR","BTC","Small Cell Lung Cancer","NSCLC","RECRUITING","2026-05-11",{"date":51,"type":52},"2026-05-13","ACTUAL",{"date":54,"type":52},"2025-06-04",{"date":56,"type":21},"2030-12",{"name":58,"class":59},"Avenzo Therapeutics, Inc.","INDUSTRY",18,{"id":62,"slug":63,"hasResults":11,"nctId":64,"briefTitle":65,"officialTitle":65,"acronym":4,"eligibilityCriteria":66,"healthyVolunteers":67,"sex":16,"minAge":68,"maxAge":69,"enrollmentInfo":70,"targetDuration":4,"studyType":72,"phases":4,"briefSummary":73,"conditions":74,"keywords":4,"overallStatus":48,"whyStopped":4,"lastUpdateSubmitDate":75,"lastUpdatePostDateStruct":76,"startDateStruct":78,"completionDateStruct":80,"leadSponsor":82,"locationsCount":84},"100578809","identification-and-validation-of-blood-based-biomarkers-for-early-detection-of-asymptomatic-lung-cancer-in-high-risk-heavy-smokers-100578809","NCT06816121","Identification and Validation of Blood-Based Biomarkers for Early Detection of Asymptomatic Lung Cancer in High-Risk Heavy Smokers","Inclusion Criteria:\n\nAll Participants:\n\n* Understands the study and can provide written informed consent\n* Willing and able to provide a blood sample\n* Age 30-80\n* Current or former smoker\n\nNon-Cancer Cohort:\n\n* Recent CT scan within 3 months AND\n* No lung nodules (Lung-RADS 1) or benign\u002Fstable nodules\n\nIndeterminate Cohort:\n\n* Recent CT scan within 12 months AND\n* Indeterminate lung nodules under active monitoring\n\nHighly Suspicious or Confirmed Lung Cancer Cohort:\n\n* Confirmed untreated lung cancer OR\n* Highly suspicious lung nodules undergoing diagnostic work-up\n\nOther Cancer Cohort:\n\n\\- Confirmed, untreated cancer associated with smoking\n\nExclusion Criteria:\n\n* Cancer diagnosis within the last 5 years\n* Systemic therapy, radiation, or surgery for cancer within 1 year prior to enrollment\n* Any history of hematologic malignancies or myelodysplasia\n* Known infection with HIV, HCV, or HBV\n* Active pregnancy",true,"30 Years","80 Years",{"count":71,"type":21},350,"OBSERVATIONAL","The goal of this observational study is to develop and evaluate a blood test for asymptomatic heavy smokers to screen for those at highest risk of developing lung cancer. The aim of this study is to develop, train, and validate a blood-based screening test designed to detect biomarkers associated with lung cancer. The study will utilize samples collected from 4 distinct cohorts.\n\n1. Participants confirmed to have lung cancer\n2. Participants without cancer\n3. Participants with moderate risk of lung cancer (indeterminate)\n4. Participants confirmed to have other types of cancers linked to smoking\n\nThe main question this study aims to answer is whether the blood test can detect existing early-stage lung cancer in heavy smokers without symptoms and to provide insights into device performance and long-term outcomes when scans show no nodules, benign findings, or indeterminate nodules.\n\nParticipants will provide blood samples at the start of the study and during follow-up visits at 12 and 24 months. Participants will share information about their smoking history, lung cancer status, and relevant medical history\n\nResearchers will collect blood samples, process them, and analyze the biomarkers at the Everest Detection laboratory. No results will be shared with participants or their doctors. The study will run for about 48 months, including a 24-month enrollment period and 24 months of follow-up to track participants' health and lung cancer outcomes.",[31],"2026-04-09",{"date":77,"type":52},"2026-04-13",{"date":79,"type":52},"2025-02-17",{"date":81,"type":21},"2029-06-30",{"name":83,"class":59},"Everest Detection, Inc.",1,{"id":86,"slug":87,"hasResults":11,"nctId":88,"briefTitle":89,"officialTitle":89,"acronym":4,"eligibilityCriteria":90,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":91,"enrollmentInfo":92,"targetDuration":4,"studyType":22,"phases":94,"briefSummary":96,"conditions":97,"keywords":4,"overallStatus":48,"whyStopped":4,"lastUpdateSubmitDate":98,"lastUpdatePostDateStruct":99,"startDateStruct":100,"completionDateStruct":102,"leadSponsor":104,"locationsCount":84},"100578367","phase-3-erector-spinae-versus-intercostal-nerve-blocks-with-liposomal-bupivacaine-for-analgesia-in-thoracic-surgery-100578367","NCT06810375","Erector Spinae Versus Intercostal Nerve Blocks With Liposomal Bupivacaine for Analgesia in Thoracic Surgery","Inclusion Criteria:\n\n* Video assisted pulmonary resection, pleurodesis or decortication\n\nExclusion Criteria:\n\n* Allergy to local anesthetics\n* Patient undergoing bilateral surgery\n* Surgery is emergent as deemed by the principal investigator","90 Years",{"count":93,"type":21},120,[95],"PHASE3","This clinical trial compares efficacy in postoperative pain management in thoracic surgery between erector spinae block versus liposomal bupivacaine injections.",[31],"2026-04-06",{"date":75,"type":52},{"date":101,"type":52},"2025-03-01",{"date":103,"type":21},"2029-02-28",{"name":105,"class":106},"George Washington University","OTHER",{"id":108,"slug":109,"hasResults":11,"nctId":110,"briefTitle":111,"officialTitle":112,"acronym":113,"eligibilityCriteria":114,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":115,"targetDuration":4,"studyType":22,"phases":117,"briefSummary":118,"conditions":119,"keywords":126,"overallStatus":48,"whyStopped":4,"lastUpdateSubmitDate":128,"lastUpdatePostDateStruct":129,"startDateStruct":131,"completionDateStruct":133,"leadSponsor":135,"locationsCount":137},"100587260","phase-1-early-phase-study-of-kesonotidein-participants-with-solid-tumours-100587260","NCT06926075","Early Phase Study of KESONOTIDE™in Participants With Solid Tumours","An Adaptive Phase I\u002FII Study of KESONOTIDE™, a Novel hGIIA-vimentin Inhibitor, in Participants With Solid Tumours","ADVICE","Inclusion Criteria:\n\n* Male or female adults (defined as ≥ 18 years of age or acceptable age according to local regulations at the time of voluntarily signing of informed consent).\n* Has an ECOG performance status score of 0 or 1.\n* Has a life expectancy of \\> 12 weeks in the opinion of the investigator.\n* Measurable or evaluable disease by CT\u002FMRI according to RECIST v1.1, except for prostate and breast cancer (bone only metastases are acceptable) and glioma.\n* Histologically or cytologically confirmed locally advanced\u002Fmetastatic solid cancers.\n* Has adequate organ function within 7 days prior to Day 1 of Cycle 1, defined as below:\n* Laboratory Value\n* Hematology\n* Platelet count \\> 100 x 109\u002FL\n* Hb \\> 9.0 g\u002FdL\n* ANC \\> 1.5 x 109\u002FL\n* Renal Function\n* Creatinine \\\u003C 1.5 x ULN\n* Hepatic Function\n* AST and ALT \\\u003C 3 x ULN for the reference laboratory or \\\u003C 5 x ULN in the presence of liver metastases\n* Total bilirubin ≤ 1.5 x ULN\n* Serum albumin ≥ 2.5 g\u002FdL\n* INR\u002FPT and APTT ≤ 1.5 x ULN\n* Male and female participants of reproductive\u002Fchildbearing potential must agree to use adequate contraceptive methods (e.g., double barrier or intrauterine contraceptive) for at least 90 days during the study and after the last dose of study drug.\n* Male participants must not freeze or donate sperm starting at screening and throughout the study period, and at least 90 days after the final study drug administration.\n* Female participants must not donate, or retrieve for their own use, ova from the time of screening and throughout the study treatment period, and at least 90 days after the final study drug administration.\n* Has failed standard of care or refused next line therapy at the present time and if approved treatment options are still available, can delay approved treatments without harm as judged by the investigator (e.g., patients requesting a break between lines of therapy).\n\nAdditional Inclusion Criteria for Parts 2 and 3:\n\n* Measurable disease (as defined for Part 1) or recognised and abnormal biomarker levels (e.g., PSA for prostate cancer, CA15.3 for breast cancer).\n* Defined diseases or disease states of interest, suitable for dose expansion.\n* Patients who have enrolled in Part 1 of the study (dose-escalation), and in the opinion of the investigator, are benefitting from treatment, may be eligible for Parts 2 and 3.\n\nExclusion Criteria:\n\n* Participants who are unable to cease any anti-inflammatory medications or statins prior to and during the study, including non-steroidal anti-inflammatories, oral steroids at any dose; topical steroids and anti-inflammatories are allowable.\n* Participants who have participated in other clinical trials and received investigational products within 4 weeks, or within five half-lives of the treatment, whichever is longer, before Cycle 1 Day 1 of the study period.\n* Previous adverse reactions which have not returned to Grade 0 or 1 according to NCI-CTCAE v5.0 (except alopecia and fatigue) at the screening visit.\n* A clinically significant active infection determined by the investigator.\n* Significant or recurrent third space accumulation (e.g., ascites or pleural effusions) according to the investigator.\n* Has a medical history of myocardial infraction or unstable angina within 6 months before enrolment.\n* Has a medical history of symptomatic CHF (New York Heart Association (NYHA) classes II-IV) or serious cardiac arrhythmia requiring treatment.\n* Has a history or presence of uncontrolled mental illness.\n* The participant is expected to be non-compliant with critical trial procedures and is not willing or able to adhere to the trial requirements during the study.\n* Participants are deemed inappropriate for this clinical trial at the discretion of the investigator.\n\nAdditional Exclusion Criteria for Parts 2 and 3:\n\n\\- Patients must not have more than 2 prior lines of therapy.",{"count":116,"type":21},80,[24,25],"This clinical trial is an adaptive study of a novel vimentin inhibitor in cancers.\n\nIt is an open label, multicentre, single ascending dose level in phase I and cohort exploration in phase II.\n\nPrimary objective is to evaluate safety and tolerability of KESONOTIDE™ as a monotherapy in participants with advanced\u002Fmetastatic solid cancers.\n\nSecondary objective is to characterise the pharmacokinetics of KESONOTIDE™. Phase I study will enrol 20-32 participants and Phase II approximately 80 participants.",[120,121,31,122,123,124,125],"Prostate Cancers","Breast Cancer","Ovarian Cancer","Glioblastoma Multiforme (GBM)","Pancreas Cancer","Skin Cancer",[127],"kesonotide, vimentin inhibotor","2026-03-15",{"date":130,"type":52},"2026-03-17",{"date":132,"type":52},"2025-11-07",{"date":134,"type":21},"2027-10-26",{"name":136,"class":59},"Filamon LTD",3,{"id":139,"slug":140,"hasResults":11,"nctId":141,"briefTitle":142,"officialTitle":143,"acronym":144,"eligibilityCriteria":145,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":146,"targetDuration":4,"studyType":22,"phases":148,"briefSummary":150,"conditions":151,"keywords":153,"overallStatus":48,"whyStopped":4,"lastUpdateSubmitDate":159,"lastUpdatePostDateStruct":160,"startDateStruct":162,"completionDateStruct":164,"leadSponsor":166,"locationsCount":84},"100589138","general-anesthesia-vs-conscious-sedation-for-radial-endobronchial-ultrasound-100589138","NCT06950515","General Anesthesia vs Conscious Sedation for Radial Endobronchial Ultrasound","A Randomized Controlled Trial of gEneral aneStheSia vs consciOUs Sedation in Radial endobronChial Ultrasound for Peripheral Pulmonary lEsions","RESSOURCE","Inclusion Criteria:\n\n* Age ≥ 18 years and ability to consent\n* Peripheral lung lesion less than 5cm in average diameter on axial CT images (A lung lesion will be considered peripheral if it is located beyond the origin of the subsegmental bronchi and presumed not to be visible endoscopically in white light during the evaluation of the CT scan by an interventional pulmonologist.)\n* Lesion deemed accessible by pEBUS by an experienced interventional pulmonologist\n* Decision by the medical team and the patient to use pEBUS as a diagnostic modality for the lung lesion\n\nExclusion Criteria:\n\n* Planned use of electromagnetic navigation, augmented fluoroscopy or robotic bronchoscopy in addition to pEBUS. The use of virtual bronchoscopy planning is permitted\n* Presence of suspicious lymph nodes (size ≥ 10mm and\u002For moderate or greater hypermetabolism) on imaging which are accessible by l-EBUS and for which rapid on-site cytological analysis will be used\n* Contraindication to bronchoscopy or biopsies such as an unstable medical condition or uncorrected coagulopathy\n* Current pregnancy\n* Lack of free and informed consent",{"count":147,"type":21},306,[149],"NA","The endoscopic investigation of lung lesions is experiencing significant growth with the increasing number of lung cancer screening programs. Peripheral endobronchial ultrasound (pEBUS) is the most widely used endoscopic technique in the investigation of peripheral pulmonary lesions (PPL). It is performed in relatively equal proportions under conscious sedation and general anesthesia by interventional pulmonologists throughout the world. Users of conscious sedation justify themselves by the fewer resources consumed and the absence of demonstration of a superior diagnostic yield of general anesthesia while users of general anesthesia claim diagnostic yield and comfort for the patient are superior with their approach. Our main objective is to compare the diagnostic yield of pEBUS under general anesthesia to that obtained under conscious sedation.",[31,152],"Peripheral Pulmonary Nodules",[154,155,156,157,158],"Lung cancer","Peripheral pulmonary nodules","bronchoscopy","peripheral endobronchial ultrasound","sedation","2026-03-04",{"date":161,"type":52},"2026-03-06",{"date":163,"type":52},"2025-09-25",{"date":165,"type":21},"2029-08",{"name":167,"class":106},"Institut universitaire de cardiologie et de pneumologie de Québec, University Laval",{"id":169,"slug":170,"hasResults":11,"nctId":171,"briefTitle":172,"officialTitle":172,"acronym":4,"eligibilityCriteria":173,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":69,"enrollmentInfo":174,"targetDuration":4,"studyType":22,"phases":176,"briefSummary":172,"conditions":177,"keywords":180,"overallStatus":184,"whyStopped":4,"lastUpdateSubmitDate":185,"lastUpdatePostDateStruct":186,"startDateStruct":188,"completionDateStruct":190,"leadSponsor":192,"locationsCount":4},"100626325","extended-reality-xr-assisted-ct-localization-of-pulmonary-nodules-100626325","NCT07434167","Extended Reality (XR)-Assisted CT Localization of Pulmonary Nodules","Inclusion Criteria:\n\n* Patients aged between 18 and 80 who are scheduled to undergo lung nodule resection surgery.\n* Patients with lung nodules smaller than 2 cm that require preoperative localization.\n* Patients with lung nodules located in the outer one-third of the lung.\n\nExclusion Criteria:\n\n* Patients requiring lobectomy.\n* Patients who have not provided written informed consent.\n* Vulnerable populations.",{"count":175,"type":21},30,[149],[31,178,179],"Metaverse","Extended Reality (XR)",[178,179,181,182,183],"Digital Twin","Localization of Pulmonary Nodules","uniportal VATS","NOT_YET_RECRUITING","2026-02-22",{"date":187,"type":52},"2026-02-25",{"date":189,"type":21},"2026-03",{"date":191,"type":21},"2026-12",{"name":193,"class":106},"National Taiwan University Hospital",{"id":195,"slug":196,"hasResults":11,"nctId":197,"briefTitle":198,"officialTitle":199,"acronym":200,"eligibilityCriteria":201,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":202,"targetDuration":4,"studyType":22,"phases":204,"briefSummary":205,"conditions":206,"keywords":220,"overallStatus":48,"whyStopped":4,"lastUpdateSubmitDate":225,"lastUpdatePostDateStruct":226,"startDateStruct":228,"completionDateStruct":230,"leadSponsor":232,"locationsCount":84},"100505180","precision-lung-cancer-survivorship-care-intervention-100505180","NCT05857995","Precision Lung Cancer Survivorship Care Intervention","Precision Lung Cancer Survivorship Care Intervention: A Randomized Controlled Trial Serving Rural Survivors and Communities","KYLEADSII","Inclusion Criteria:\n\n* Have been diagnosed with lung cancer\n* Reside in a rural county as determined by a Rural Urban Continuum Code (RUC) of 4 or higher\n* Be at least 18 years of age or older\n* Be able to communicate effectively in English\n\nExclusion Criteria:\n\n* Have significant psychiatric disturbance that requires a higher level of care\n* Have substance abuse\u002Fdependence that requires a higher level of care\n* Are participating in another lung cancer survivorship care intervention\n* Have previously participated in the Kentucky LEADS Lung Cancer Survivorship Care Program",{"count":203,"type":21},300,[149],"The overarching goal of the Kentucky LEADS Collaborative Lung Cancer Survivorship Care program is to reduce the burden of lung cancer by offering an innovative survivorship care approach that improves lung cancer quality of life, overcomes lung cancer stigma, and helps survivors engage with care. The project involves a two-group parallel randomized clinical trial comparing the impact of the Kentucky LEADS Collaborative Lung Cancer Survivorship Care program (KLCLCSC) among lung cancer survivors (N=300) against an enhanced usual care condition (bibliotherapy+assessment) on quality of life outcomes.",[39,207,208,209,210,211,212,213,214,215,216,217,218,219,31],"Pulmonary Neoplasm","Neoplasms, Lung","Neoplasms, Pulmonary","Neoplasm, Pulmonary","Cancer, Lung","Cancers, Lung","Pulmonary Cancer","Cancer, Pulmonary","Cancers, Pulmonary","Pulmonary Cancers","Cancer of the Lung","Cancer of Lung","Pulmonary Neoplasms",[221,222,223,224],"Survivorship","Quality of Life","Behavioral Oncology","Psychosocial Oncology","2026-02-19",{"date":227,"type":52},"2026-02-23",{"date":229,"type":52},"2024-08-16",{"date":231,"type":21},"2028-03-31",{"name":233,"class":106},"Jerod L Stapleton, PhD",{"id":235,"slug":236,"hasResults":11,"nctId":237,"briefTitle":238,"officialTitle":239,"acronym":240,"eligibilityCriteria":241,"healthyVolunteers":11,"sex":16,"minAge":242,"maxAge":4,"enrollmentInfo":243,"targetDuration":245,"studyType":72,"phases":4,"briefSummary":246,"conditions":247,"keywords":252,"overallStatus":48,"whyStopped":4,"lastUpdateSubmitDate":262,"lastUpdatePostDateStruct":263,"startDateStruct":265,"completionDateStruct":267,"leadSponsor":269,"locationsCount":84},"100597373","shape-sensing-robotic-assisted-bronchoscopy-for-diagnosis-of-peripheral-pulmonary-nodules-in-korea-100597373","NCT07057648","Shape-Sensing Robotic-Assisted Bronchoscopy for Diagnosis of Peripheral Pulmonary Nodules in Korea","Shape-sensing Robotic-assisted Bronchoscopy (ssRAB) for Diagnosis of Peripheral Pulmonary Nodules: A Prospective Cohort Study in Korea (the ULSAN-ION Study)","ULSAN-ION","Inclusion Criteria:\n\n* Adults aged 19 years or older\n* Solid or part-solid peripheral pulmonary nodules confirmed on chest computed tomography (CT)\n* Patients requiring histological diagnosis as determined by the treating physician\n* Patients eligible for bronchoscopy procedure\n* Ability to provide written informed consent\n* Eastern Cooperative Oncology Group (ECOG) performance status 0-2 or equivalent functional status allowing procedure under sedation or general anesthesia\n\nExclusion Criteria:\n\n* Pure ground glass opacity nodules\n* Bleeding tendency defined as platelet count less than 50,000\u002FμL or International Normalized Ratio (INR) greater than 1.5\n* Severe cardiopulmonary dysfunction precluding deep sedation or general anesthesia\n* Pregnant or breastfeeding women\n* Life expectancy less than 6 months as assessed by the treating physician\n* Inability or unwillingness to provide informed consent\n* Absolute contraindication to bronchoscopy including:\n\n  * Severe hypoxemia (oxygen saturation \\\u003C90% on room air)\n  * Severe pulmonary hypertension\n  * Recent myocardial infarction (within 6 weeks)\n  * Unstable angina\n  * Malignant arrhythmias\n* Participation in another interventional clinical trial that may interfere with study procedures or outcomes","19 Years",{"count":244,"type":21},100,"6 Months","What is this study about? This study tests a new robotic technology to take tissue samples from lung nodules (small spots in the lungs). Some lung nodules are cancer, but doctors need a tissue sample to know for sure.\n\nWhat is the problem? Current methods to get tissue from lung nodules only work about 7 out of 10 times. When they don't work, doctors may need riskier procedures.\n\nWhat is the new technology? The new technology is called robotic bronchoscopy (ssRAB). It uses a robot with special sensors to guide a thin tube more accurately to lung nodules than current methods.\n\nWho can join? Adults aged 19 or older who have lung nodules that need tissue sampling and are healthy enough for the procedure.\n\nWhat happens? Participants will have the robotic procedure while asleep under anesthesia. The robot guides a thin tube to the lung nodule to take a small tissue sample. Participants are watched for problems and followed for 6 months.\n\nWhat are the risks and benefits? The new technology may be more accurate and safer than current methods. The main risks are small chance of lung collapse or bleeding, similar to regular procedures.\n\nWhy is this important? This study will show if the new robotic technology works well and is safe in Korea. If successful, it could help diagnose lung cancer earlier and more accurately.\n\nThis study will include 100 people at Ulsan University Hospital in Korea.",[248,249,250,31,251],"Lung Nodules","Peripheral Lung Lesions","Pulmonary Nodules","Bronchoscopy",[253,254,255,256,257,248,258,259,260,261],"Shape-sensing robotic-assisted bronchoscopy","ssRAB","Robotic bronchoscopy","Peripheral lung nodules","Diagnostic yield","Navigation bronchoscopy","Lung biopsy","Korea","Prospective cohort","2026-02-10",{"date":264,"type":52},"2026-02-13",{"date":266,"type":52},"2025-07-09",{"date":268,"type":21},"2027-05-31",{"name":270,"class":106},"Ulsan University Hospital",{"id":272,"slug":273,"hasResults":11,"nctId":274,"briefTitle":275,"officialTitle":276,"acronym":277,"eligibilityCriteria":278,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":279,"targetDuration":4,"studyType":22,"phases":281,"briefSummary":282,"conditions":283,"keywords":284,"overallStatus":48,"whyStopped":4,"lastUpdateSubmitDate":291,"lastUpdatePostDateStruct":292,"startDateStruct":294,"completionDateStruct":296,"leadSponsor":298,"locationsCount":137},"100577117","an-evaluation-of-dose-escalation-for-intrathoracic-tumours-100577117","NCT06794125","An Evaluation of Dose-escalation for Intrathoracic Tumours","A Phase II\u002FIII Randomized Evaluation of Dose-escalation With Esophageal-sparing for Palliation of Intrathoracic Tumours (PREVENT)","PREVENT-LUNG","Inclusion Criteria:\n\n* Intrathoracic tumour requiring palliative radiation, either for palliation of symptoms or prevention of progression that is expected to cause symptoms in the next 6 months (in the judgement of the enrolling investigator)\n* Willingness and ability to provide informed consent\n* Eastern Cooperative Oncology Group performance status 0-3\n* Age 18 years or older\n* Prior or planned systemic treatment (chemotherapy, immunotherapy, targeted agents) is permissible at the discretion of the treating medical oncologist\n* Concurrent palliative radiotherapy to other metastatic sites is permissible at the discretion of the treating radiation oncologist.\n* Life expectancy greater than 3 months\n\nExclusion Criteria:\n\n* Prior thoracic radiotherapy which, in the opinion of the treating of radiation oncologist, precludes the delivery of further thoracic radiotherapy. If there has been prior thoracic radiotherapy, a composite of all RT plans must be created, and the dose constraints herein must still be met. An allowance for 10 percent repair is permitted if at least 12 months have passed between the prior radiotherapy and the trial protocol specified radiotherapy.\n* Serious medical comorbidities which, in the opinion of the treating radiation oncologist, preclude the delivery of radiotherapy. This includes interstitial lung disease.\n* Pregnant or lactating women\n* Inability to attend the full course of radiotherapy or planned follow-up visits",{"count":280,"type":21},141,[149],"This is a pragmatic trial with patients randomized between standard of care palliative thoracic radiation therapy (RT) vs. hypofractionated, dose-escalated, esophageal-sparing (HD-ES) intensity modulated radiation therapy (IMRT).\n\nThe investigators hypothesize that the use of advanced radiation planning techniques to optimize dose to esophagus will permit the safe delivery of a modestly dose-escalated five-fraction course of palliative radiation to intrathoracic malignancies. This approach aims to deliver higher biologically effective doses while improving toxicity when compared to conventional approaches with the goal of prolonging high-quality overall survival.",[31],[285,286,287,288,289,290],"lung cancer","radiation therapy","hypofractionated","esophageal-sparing","dose-escalated","intrathoracic","2026-02-03",{"date":293,"type":52},"2026-02-04",{"date":295,"type":52},"2025-09-03",{"date":297,"type":21},"2029-03-01",{"name":299,"class":106},"Chris Goodman",{"id":301,"slug":302,"hasResults":11,"nctId":303,"briefTitle":304,"officialTitle":305,"acronym":4,"eligibilityCriteria":306,"healthyVolunteers":11,"sex":16,"minAge":307,"maxAge":4,"enrollmentInfo":308,"targetDuration":4,"studyType":22,"phases":310,"briefSummary":311,"conditions":312,"keywords":4,"overallStatus":48,"whyStopped":4,"lastUpdateSubmitDate":313,"lastUpdatePostDateStruct":314,"startDateStruct":316,"completionDateStruct":318,"leadSponsor":320,"locationsCount":322},"100567904","a-study-on-the-improvement-of-postoperative-symptoms-and-survival-benefits-of-modified-bufei-decoction-in-elderly-patients-with-lung-cancer-undergoing-radical-surgery-100567904","NCT06674252","A Study on the Improvement of Postoperative Symptoms and Survival Benefits of Modified Bufei Decoction in Elderly Patients With Lung Cancer Undergoing Radical Surgery","A Randomized Controlled Multicenter Study on the Improvement of Postoperative Symptoms and Survival Benefits of Modified Bufei Decoction in Elderly Patients With Lung Cancer Undergoing Radical Surgery","Inclusion Criteria:\n\n* Patients with postoperative lung cancer who have clear histological or cytological diagnosis.\n\n  * Age ≥ 65 years old, both male and female are eligible. According to the MDASI-TCM scale evaluation, any of the three symptoms of cough, fatigue, and shortness of breath should score ≥ 4 points, or the sum of the three should score ≥ 6 points.\n\n    * The heart function is basically normal; ALT\u002FAST is within 2 times the normal value; SCr is within the normal range.\n\nTraditional Chinese medicine syndrome differentiation is characterized by deficiency of both lungs and kidneys.\n\nExclusion Criteria:\n\n* Patients with severe pulmonary infections. ⑵. Patients with mental illness. ⑶. Patients with depression.","65 Years",{"count":309,"type":21},174,[149],"This is a randomized double-blind placebo-controlled phase II clinical study that included patients with symptoms such as cough, shortness of breath, and fatigue after lung cancer resection surgery. They were given orally modified Bufei Tang granules twice a day for 28 days, with one packet taken orally with water. Using the MDASI-TCM symptom scoring system, evaluate the scores of symptoms such as cough, shortness of breath, and fatigue before and after the experiment, and calculate the difference in scores between the control group and the experimental group before and after the experiment.",[31],"2026-01-26",{"date":315,"type":52},"2026-01-27",{"date":317,"type":52},"2025-06-13",{"date":319,"type":21},"2027-12",{"name":321,"class":106},"Peking University Cancer Hospital & Institute",2,{"id":324,"slug":325,"hasResults":11,"nctId":326,"briefTitle":327,"officialTitle":327,"acronym":328,"eligibilityCriteria":329,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":330,"targetDuration":4,"studyType":22,"phases":332,"briefSummary":333,"conditions":334,"keywords":338,"overallStatus":48,"whyStopped":4,"lastUpdateSubmitDate":347,"lastUpdatePostDateStruct":348,"startDateStruct":350,"completionDateStruct":352,"leadSponsor":354,"locationsCount":356},"100589890","sustainable-implementation-of-the-excel-exercise-oncology-program-across-canada-100589890","NCT06960291","Sustainable Implementation of the EXCEL Exercise Oncology Program Across Canada","EXCEL","Inclusion Criteria:\n\n* have or had a diagnosis of cancer;\n* be 18 years or older;\n* be able to participate in low-intensity levels of activity, at minimum;\n* be pretreatment, or receiving active cancer treatment (i.e., surgery, systemic therapy and radiation therapy), have received cancer treatment within the past 3 years, or if beyond 3 years since treatment completion, have a referral from their healthcare team indicating they have side effects from cancer treatment or the cancer itself, that could be improved or managed with exercise;\n* be able to provide informed written consent in English or French\n\nExclusion Criteria:\n\n* does not or did not have a cancer diagnosis\n* is under the age of 18\n* is unable to participate in mild exercise, at minimum\n* is not pretreatment, or receiving active cancer treatment (i.e., surgery, systemic therapy and radiation therapy), has not received cancer treatment within the past 3 years, or if beyond 3 years since treatment completion, doesn't have side effects from cancer treatment or the cancer itself, that could be improved or managed with exercise\n* unable to read\u002Fwrite in English\n* for online programs, does not have internet or computer access",{"count":331,"type":21},740,[149],"EXCEL will provide online and, where feasible, in-person exercise programs to individuals living with and beyond cancer (ILWBC). Research has shown that targeted programs that include tailored exercise prescriptions are more successful in helping individuals with chronic disease to incorporate physical activity and exercise into their daily routines. While ILWBC are advised by healthcare professionals (HCPs) to engage in exercise, there is a lack of cancer-specific exercise programs and cancer-trained exercise specialists in Canada, outside of the research setting. Considering the negative impact cancer and its treatments have on fitness and physical activity levels, community-based efforts towards improving access, uptake and maintenance of exercise programming are needed.\n\nThis study will evaluate the benefits of a community-based or online EXCEL exercise program for people living with and beyond cancer across Canada, using a streamlined intake process compared to the original EXCEL Study (HREBA.CC-20-0098, NCT04478851). This 8 to 12-week program (intervention) will be delivered in-person or over virtual platform. It includes twice weekly supervised exercise classes.",[335,120,336,337,31],"Cancer","Breast Cancers","Colon Cancer",[339,340,341,342,343,344,345,346],"Exercise oncology","Exercise","Physical activity","community program","online exercise","cancer survivor","individual living with and beyond cancer","quality of life","2025-10-02",{"date":349,"type":52},"2025-10-07",{"date":351,"type":52},"2025-03-11",{"date":353,"type":21},"2026-11-30",{"name":355,"class":106},"University of Calgary",5,{"id":358,"slug":359,"hasResults":11,"nctId":360,"briefTitle":361,"officialTitle":362,"acronym":4,"eligibilityCriteria":363,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":364,"targetDuration":4,"studyType":22,"phases":366,"briefSummary":367,"conditions":368,"keywords":371,"overallStatus":48,"whyStopped":4,"lastUpdateSubmitDate":376,"lastUpdatePostDateStruct":377,"startDateStruct":378,"completionDateStruct":380,"leadSponsor":382,"locationsCount":84},"100588495","phase-1-an-open-label-phase-i-clinical-trial-of-super1-tcr-t-in-ny-eso-1-positive-patients-with-advanced-solid-tumors-100588495","NCT06942143","An Open-label, Phase I Clinical Trial of Super1 TCR-T in NY-ESO-1-positive Patients With Advanced Solid Tumors","An Open-label, Phase I Clinical Trial of Autologous T Cells Transduced With NY-ESO-1 Antigen-specific High-affinity T Cell Receptors in NY-ESO-1-positive Patients With Advanced Solid Tumors","Inclusion Criteria:\n\n1. Sign informed consent before conducting any trial-related activities;\n2. Age of 18-75 years old, male or female;\n3. Patients with first-line treatment failure;\n4. Measurable lesions according to RECIST1.1 criteria.\n5. During the trial screening period, the following two screening criteria must be met (by the sponsor) :\n\n   * HLA-A\\*02 positive;\n   * The positive rate of NYESO-1 immunohistochemical staining was ≥20%.\n6. ECOG score 0-1;\n7. The expected survival time is more than 3 months;\n8. Antineoplastic drugs and treatments were not allowed for 4 weeks before TCR-T cell infusion;\n9. Echocardiography showed left ventricular ejection fraction ≥50%;\n10. Laboratory test results should at least meet the following specified indicators:\n\n    * WBC ≥3.0×109\u002FL;\n    * Absolute neutrophil count (ANC) ≥1.5×109\u002FL;\n    * Absolute lymphocyte count (ALC) ≥1.0×109\u002FL;\n    * platelet (PLT) ≥75×109\u002FL;\n    * hemoglobin ≥10g\u002FdL (no blood transfusion in the past 7 days);\n    * Prothrombin time or INR≤1.5x upper limit of normal unless receiving anticoagulant therapy;\n    * Partial prothrombin time (APTT) ≤1.5x upper limit of normal time, unless receiving anticoagulant therapy;\n    * 24-hour creatinine clearance ≥60mL\u002F min;\n    * Aspartate aminotransferase (AST\u002FSGOT) ≤2.5×ULN;\n    * alanine aminotransferase (ALT\u002FSGPT) ≤2.5×ULN;\n    * Total bilirubin (TBIL) ≤1.5×ULN\n11. Negative pregnancy tests in women of childbearing potential prior to study treatment; Consent must be given to use effective contraception during treatment.\n12. During the whole period of the trial, I can regularly visit the enrolled research institutions for relevant testing, evaluation and management.\n\nExclusion Criteria:\n\n1. Patients who received major surgery, conventional chemotherapy, large area radiotherapy, immunotherapy or biological therapy within 4 weeks before entering the trial;\n2. Known to produce allergic reactions to any component of the trial treatment;\n3. no recovery from previous surgery or treatment-related adverse events to ≤ grade 2 CTCAE;\n4. Poorly controlled hypertension (systolic blood pressure \\> 160mmHg and\u002For diastolic blood pressure \\> 90mmHg) or clinically significant (e.g., active) cardio-cerebrovascular disease; Cerebrovascular accident (within 6 months before the signing of informed consent), myocardial infarction (within 6 months before the signing of informed consent), unstable angina, congestive heart failure of New York Heart Association class II or higher (Appendix), or severe arrhythmia that could not be controlled with medications or that had the potential to affect study treatment; Electrocardiogram (ECG) was significantly abnormal or the mean QTc interval was ≥450 msec on three consecutive occasions.\n5. Combined with other serious organic diseases and mental disorders;\n6. Have active systemic infection requiring treatment, including active tuberculosis, known HIV positivity, or clinically active hepatitis A, B, or C; (Virus carriers should be excluded)\n7. Patients with autoimmune diseases: those with a history of inflammatory bowel disease or a history of autoimmune diseases (such as systemic lupus erythematosus, vasculitis, and invasive lung disease) judged by the investigators to be not suitable for this study should be excluded; (Patients with vitiligo are not excluded).\n8. Administration of chronic systemic cortisone steroids, hydroxyurea, and immunomodulatory agents (e.g., interleukin-2, interferon-α or γ, GM-CSF, mTOR inhibitors, cyclosporine, thymosin, etc.) within 4 weeks prior to cell therapy.\"\n9. History of organ transplantation, autologous\u002Fallogeneic stem cell transplantation and renal replacement therapy;\n10. Known uncontrolled diabetes mellitus, pulmonary fibrosis, interstitial lung disease, acute lung disease or liver failure;\n11. Known alcohol and\u002For drug abuse;\n12. Pregnant or lactating women;\n13. Trial participants with any coexisting medical conditions or diseases judged by the investigators to be likely to impair the conduct of the trial;\n14. No legal capacity\u002Flimited capacity.",{"count":365,"type":21},15,[24],"This study was a phase I safety and tolerability clinical trial conducted in a single-center, open-label, 3+3 design with dose escalation.",[369,31,370],"Sarcoma","Melanoma",[372,373,374,375],"Cell therapy","Immunotherapy","Solid tumor","NY-ESO-1 TCR-T","2025-08-26",{"date":295,"type":52},{"date":379,"type":52},"2025-05-22",{"date":381,"type":21},"2027-06-25",{"name":383,"class":59},"Guangzhou FineImmune Biotechnology Co., LTD.",{"id":385,"slug":386,"hasResults":11,"nctId":387,"briefTitle":388,"officialTitle":389,"acronym":4,"eligibilityCriteria":390,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":391,"targetDuration":4,"studyType":22,"phases":393,"briefSummary":394,"conditions":395,"keywords":396,"overallStatus":48,"whyStopped":4,"lastUpdateSubmitDate":399,"lastUpdatePostDateStruct":400,"startDateStruct":402,"completionDateStruct":404,"leadSponsor":406,"locationsCount":137},"100587265","acupuncture-combined-with-pd-1pd-l1-inhibitors-for-advanced-lung-cancer-100587265","NCT06926140","Acupuncture Combined With PD-1\u002FPD-L1 Inhibitors for Advanced Lung Cancer","Effectiveness of Acupuncture Combined With PD-1\u002FPD-L1 Inhibitors for Advanced Lung Cancer：A Randomized Controlled Clinical Study","Inclusion criteria:\n\n* Age 18-75 years;\n* ECOG\u002FPS score of grade 0-1 and expected survival ≥ 3 months;\n* Non-small cell lung cancer AJCC lung cancer staging of stage IIIB-IV, or small cell lung cancer staging of extensive stage;\n* PD-L1 immunohistochemistry detection of tumor cell positive proportion score (TPS) \\\u003C50%;\n* Non-small cell lung cancer adenocarcinoma patients do not have EGFR-sensitive mutations, ALK fusions, ROS1 fusions, BRAFV600 mutations, NTRK fusions, RET fusions, MET14 skipping mutations, and amplified gene-driven mutations by genetic testing;\n* Patients with no previous systemic therapy\u002Ffirst-line treatment;\n* Patients suitable for chemotherapy combined with immunotherapy;\n* Traditional Chinese Medicine (TCM) diagnosis of Qi Depression;\n* Having at least 1 measurable tumor lesion (diameter \\> 1cm) or lymph node short diameter ≥ 1.5cm;\n* Sign the informed consent form and voluntarily participate in this study.\n\nExclusion criteria:\n\n* Combined with other primary malignant tumors;\n* Those who have contraindications to immunotherapy after basic assessment of immunotherapy;\n* Those with autoimmune diseases or those who need long-term treatment with systemic steroids or immunosuppressants;\n* Those with combined serious and uncontrolled primary diseases of heart, cerebrovascular, liver, kidney, hematopoietic system and so on;\n* Those with metal allergy or severe fear of needles;\n* Those who are pregnant or breastfeeding;\n* Those who are unable to cooperate to complete the assessment due to mental disorder, intellectual or language impairment;\n* Those with active severe infectious or inflammatory diseases;\n* Those who have received acupuncture treatment or other clinical trials within 1 month prior to randomization;\n* In the judgment of the investigator, persons who have a concomitant medical condition that seriously jeopardizes the safety of the participant or interferes with the completion of the study, or who are deemed to have other reasons for not being suitable for enrollment.",{"count":392,"type":21},240,[149],"This study will be an evaluation of the efficacy and safety of acupuncture to enhance the response rate of immunotherapy in advanced lung cancer. The main questions it aims to answer are 1. Does acupuncture heighten the response rate of immunotherapy in advanced lung cancer? 2. Does acupuncture heighten the safety of immunotherapy in advanced lung cancer? Researchers will compare acupuncture to sham acupuncture to see if acupuncture could enhance the response rate of immunotherapy in advanced lung cancer. Both groups will receive a standard anti-tumor Western medical treatment regimen (PD-1\u002FPD-L1 inhibitor combined with chemotherapy), and the experimental and control groups will be treated with 4 cycles of acupuncture or sham-acupuncture on top of the anti-tumor treatment regimen, respectively. Patients were followed up every three weeks for the first three months and every three months thereafter to record any disease progression, adverse events, survival or mortality status, and so on.",[31],[285,397,398],"acupuncture","immunotherapy","2025-07-21",{"date":401,"type":52},"2025-07-24",{"date":403,"type":52},"2025-06-21",{"date":405,"type":21},"2028-07-31",{"name":407,"class":106},"Guang'anmen Hospital of China Academy of Chinese Medical Sciences",{"id":409,"slug":410,"hasResults":11,"nctId":411,"briefTitle":412,"officialTitle":413,"acronym":4,"eligibilityCriteria":414,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":415,"targetDuration":4,"studyType":72,"phases":4,"briefSummary":416,"conditions":417,"keywords":419,"overallStatus":48,"whyStopped":4,"lastUpdateSubmitDate":422,"lastUpdatePostDateStruct":423,"startDateStruct":425,"completionDateStruct":427,"leadSponsor":429,"locationsCount":84},"100596444","assessment-the-effectiveness-of-btva-in-copd-and-ablation-in-pulmonary-nodules-by-pulmonary-mri-100596444","NCT07045532","Assessment the Effectiveness of BTVA in COPD and Ablation in Pulmonary Nodules by Pulmonary MRI","Assessment the Effectiveness of Bronchoscopic Thermal Vapor Ablation in Chronic Obstructive Pulmonary Disease and Ablation in Pulmonary Nodules by Pulmonary Magnetic Resonance Imaging","Inclusion Criteria:\n\n1. Age \\>18 years old;\n2. Patients with pulmonary nodules: patients with pulmonary nodules indicated by chest CT, pathologically diagnosed as malignant, and receiving ablative treatment, including transthoracic and percutaneous ablative methods, including radiofrequency, microwave, and freezing;\n3. COPD patients: patients diagnosed with COPD according to the GOLD principle and treated with thermal steam ablation for COPD;\n4. Understand the study and sign the informed consent.\n\nExclusion Criteria:\n\n1. Chest CT nodules in patients with pulmonary nodules were pure ground glass nodules;\n2. Patients who install or carry metal implants such as cardiac pacemakers, heart stents, artificial heart valves in the body or suffer from claustrophobia, allergy to contrast media and other reasons are not suitable for MRI examination;\n3. severe cardiopulmonary dysfunction and other diseases that may significantly increase the risk of ablation surgery;\n4. Patients with severe COPD exacerbation or pneumonia in the past four weeks;",{"count":244,"type":21},"A Clinical Study Based on Magnetic Resonance Imaging of the Lungs to Assess the Efficacy of Thermal Vapor Ablation and Pulmonary Nodule Ablation in Chronic Obstructive Pulmonary Disease After Surgery.\n\nThe efficacy of hot steam ablation for chronic obstructive pulmonary disease was evaluated using the innovative MRI sequence PREFUL\\_MRI, and the efficacy of pulmonary nodule ablation was evaluated using the innovative MRI sequence GRASP\\_MRI.",[418,31],"COPD",[420,418,154,421],"MRI","ablation","2025-06-22",{"date":424,"type":52},"2025-07-01",{"date":426,"type":52},"2024-09-01",{"date":428,"type":21},"2026-09-30",{"name":430,"class":106},"Shanghai Chest Hospital",{"id":432,"slug":433,"hasResults":11,"nctId":434,"briefTitle":435,"officialTitle":436,"acronym":4,"eligibilityCriteria":437,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":438,"targetDuration":4,"studyType":22,"phases":440,"briefSummary":441,"conditions":442,"keywords":444,"overallStatus":48,"whyStopped":4,"lastUpdateSubmitDate":447,"lastUpdatePostDateStruct":448,"startDateStruct":450,"completionDateStruct":452,"leadSponsor":454,"locationsCount":84},"100575699","phase-2-spatial-fragmentation-combined-with-low-dose-radiotherapy-for-immunotherapy-combined-with-chemotherapy-resistant-locally-advanced-or-advanced-non-small-cell-lung-cancer-100575699","NCT06775678","Spatial Fragmentation Combined With Low-dose Radiotherapy for Immunotherapy Combined With Chemotherapy-resistant Locally Advanced or Advanced Non-small Cell Lung Cancer","A Single-centre Phase II Clinical Study of Spatially Fragmentation Radiotherapy Combined With Low-dose Radiotherapy for Reversal of Immunotherapy Combined With Chemotherapy Resistance in Locally Advanced Inoperable or Advanced Non-small Cell Lung Cancer","Inclusion Criteria:\n\n1. Sign the informed consent form.\n2. Be at least 18 years old.\n3. Have a Karnofsky Performance Status (KPS) score of 70 or higher and an expected survival of more than 3 months.\n4. Have histopathological evidence of small cell lung cancer, lung adenocarcinoma, or lung squamous cell carcinoma.\n5. Have received prior immunotherapy and experienced disease progression.\n6. The site targeted for radiotherapy has not been previously irradiated or it has been at least 6 months since the last radiotherapy.\n\nExclusion Criteria:\n\n1. The patient has lesions that are not suitable for radiotherapy: malignant pleural effusion, ascites, meningeal metastasis, etc.\n2. The patient has other serious comorbidities, such as myocardial infarction occurring within 6 months, severe arrhythmia, mental illness, etc., is unable to complete the treatment, or has an expected survival period of less than 3 months.\n3. The patient has severe organ dysfunction, such as liver failure, cardiopulmonary failure, etc., and is difficult to tolerate radiotherapy.\n4. The patient currently has a severe infection.\n5. The patient has a known or suspected active autoimmune disease (congenital or acquired), such as uveitis, enteritis, hepatitis, hypophysitis, vasculitis, nephritis, thyroiditis, etc. (Patients with vitiligo or those with cured childhood asthma can be included; patients with type 1 diabetes who have good insulin control can also be included).\n6. The patient has experienced grade 3 or above cardiac or liver toxicity reactions or grade 4 toxicity reactions in other organs during previous immunotherapy.\n7. Other situations where reviewers consider there are sufficient reasons for disqualification from the registered study: such as potential situations inconsistent with the clinical protocol.",{"count":439,"type":21},84,[25],"The purpose of this study was to evaluate the effect of immunotherapy combined with spatial fractionation radiotherapy and low dose radiotherapy on the prognosis of patients with advanced lung cancer under specific dose regimens (spatial fractionation radiotherapy: high dose region: 800-1200cGy × 3f, low dose region: 100-300cGy × 5f; low dose radiotherapy area: 100-300cGy × 5f). Through the phase II clinical trial, to determine the efficacy and safety of the combined treatment model in advanced lung cancer and its effect on the immune microenvironment of patients, so as to provide scientific basis for the optimization of treatment regimen for advanced lung cancer.",[31,443],"Radiation Treatment for Tumors",[445,446,31,373],"Spatially Fractionated Radiation Treatment","low dose radiotherapy","2025-06-15",{"date":449,"type":52},"2025-06-17",{"date":451,"type":52},"2024-10-01",{"date":453,"type":21},"2028-01-28",{"name":455,"class":106},"Tianjin Medical University Cancer Institute and Hospital",{"id":457,"slug":458,"hasResults":11,"nctId":459,"briefTitle":460,"officialTitle":460,"acronym":4,"eligibilityCriteria":461,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":69,"enrollmentInfo":462,"targetDuration":4,"studyType":22,"phases":464,"briefSummary":465,"conditions":466,"keywords":468,"overallStatus":184,"whyStopped":4,"lastUpdateSubmitDate":470,"lastUpdatePostDateStruct":471,"startDateStruct":473,"completionDateStruct":475,"leadSponsor":477,"locationsCount":4},"100591150","application-of-extended-reality-xr-assisted-ct-guided-localization-of-pulmonary-nodules-in-thoracoscopic-sublobar-resection-100591150","NCT06976684","Application of Extended Reality (XR)-Assisted CT-Guided Localization of Pulmonary Nodules in Thoracoscopic Sublobar Resection.","Inclusion Criteria:\n\n* Patients aged between 18 and 80 who are scheduled to undergo lung nodule resection surgery.\n* Patients with lung nodules smaller than 2 cm that require preoperative localization.\n* Patients with lung nodules located in the outer one-third of the lung.\n\nExclusion Criteria:\n\n* Patients younger than 18 or older than 80 years.\n* Patients requiring lobectomy.\n* Patients who have not provided written informed consent.\n* Vulnerable populations.",{"count":463,"type":21},20,[149],"Reality (XR)-Assisted CT-Guided Localization",[31,178,467,179],"Virtual Surgical Simulation",[178,469,179,250,181],"virtual surgical simulation","2025-05-13",{"date":472,"type":52},"2025-05-16",{"date":474,"type":21},"2025-05",{"date":476,"type":21},"2025-12",{"name":193,"class":106},{"id":479,"slug":480,"hasResults":11,"nctId":481,"briefTitle":482,"officialTitle":483,"acronym":4,"eligibilityCriteria":484,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":485,"targetDuration":4,"studyType":72,"phases":4,"briefSummary":486,"conditions":487,"keywords":4,"overallStatus":48,"whyStopped":4,"lastUpdateSubmitDate":491,"lastUpdatePostDateStruct":492,"startDateStruct":494,"completionDateStruct":496,"leadSponsor":498,"locationsCount":84},"100588109","18f-labeled-fap-targeted-molecular-probe-in-early-tumor-diagnosis-100588109","NCT06937112","18F Labeled FAP Targeted Molecular Probe in Early Tumor Diagnosis","Clinical Application of a Novel 18F Labeled Fibroblast Activation Protein (FAP) Targeted Molecular Probe in Early Tumor Diagnosis","Inclusion Criteria:\n\n\\- 1. Volunteer for the trial, with the patient or their legal guardian signing the informed consent form; 2. Volunteers are not limited by gender, and the age range is from 18 to 75 years old, including both ends; 3. Other imaging examination methods (CT, MRI, etc.) revealed tumor occupying lesions; 4. Patients with lung cancer, thyroid cancer, pancreatic cancer, melanoma, and neuroendocrine tumors who can obtain the final pathological results.\n\n5\\. Kidney: GFR \\> 50 ml\u002Fmin, ERPF \\> 280 ml\u002Fmin, platelet count (PLT) \\> 75,000\u002FμL, white blood cell (WBC) \\> 3,000\u002FμL, alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels less than 3 times the normal value.\n\nExclusion Criteria:\n\n* 1\\. Individuals with a history of allergies to similar drugs (drugs with similar chemical or biological components to FAPI), allergic constitution, or current allergic diseases; 2. Those who are currently conducting clinical research on other drugs or have participated in any clinical research on drugs (excluding vitamins and minerals); 3. There are other clinical problems that are difficult to control (such as HIV, hepatitis C virus infection or active hepatitis B, or other serious chronic infections and serious mental, neurological, cardiovascular, respiratory and other system diseases); 4. Red blood cell RBC\\\u003C4 × 1012, white blood cell WBC\\\u003C3 × 109, hemoglobin\\\u003C110g\u002FL, PLT\\\u003C75000×109； 5. Significant abnormalities in liver and kidney function, with GFR less than 50 ml\u002Fmin; 6. Tumor burden greater than 50%, or significant spinal cord compression; 7. Expected survival period is less than six months; Chemotherapy within June; 8. Having severe acute comorbidities or severe refractory mental disorders; 9. Pregnant and lactating women (where pregnancy is defined as a positive urine pregnancy study); 10. Patients whose physical condition is not suitable for radiation examination; 11. Other situations that researchers consider unsuitable for participating in the experiment.",{"count":463,"type":21},"Evaluate the safety of the novel FAP targeted molecular probe 18F-FAPI-YQ104 labeled with radioactive isotopes in clinical applications and verify its effectiveness in tumor diagnosis.",[31,488,489,490],"Pancreatic Cancer","Neuroendocrine Tumors","Thyroid Cancer","2025-04-18",{"date":493,"type":52},"2025-04-22",{"date":495,"type":52},"2025-04-10",{"date":497,"type":21},"2026-03-31",{"name":499,"class":106},"Nanjing First Hospital, Nanjing Medical University",{"id":501,"slug":502,"hasResults":11,"nctId":503,"briefTitle":504,"officialTitle":504,"acronym":505,"eligibilityCriteria":506,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":507,"targetDuration":4,"studyType":22,"phases":509,"briefSummary":510,"conditions":511,"keywords":4,"overallStatus":48,"whyStopped":4,"lastUpdateSubmitDate":513,"lastUpdatePostDateStruct":514,"startDateStruct":516,"completionDateStruct":518,"leadSponsor":520,"locationsCount":322},"100364461","analysis-of-circulating-tumor-markers-in-blood-100364461","NCT04025541","Analysis of Circulating Tumor Markers in Blood","ALCINA2","Inclusion Criteria:\n\n1. Patient presenting an invasive tumoral pathology (proved or suspected), whatever is the location or the stage,\n2. Man or woman ≥ 18 years,\n3. Obtaining of the informed consent signed before any procedure of specific preselection on approval.\n\nExclusion Criteria:\n\n1. Private persons of freedom or under guardianship,\n2. Patient whose regular follow-up is impossible for psychological, family, social or geographical reasons,\n3. Pregnant woman and\u002For breast-feeding,\n4. Unaffiliated patient to Social Protection System,",{"count":508,"type":21},992,[149],"The circulating tumoral biomarkers in the blood are the object of numerous researches for several decades. The potential clinical interests of these circulating biomarkers are diagnostic, prognostic, predictive of the efficiency of targeted therapies (according to the mutational profile of the cancer), and could allow the study of the mechanisms of resistance under process. In the multiplicity of these blood potential biomarkers joins a permanent evolution of the technological means used to detect them\u002Fto quantify, as well as to estimate their clinical utility.",[335,121,369,31,512,337],"Glioma","2025-03-27",{"date":515,"type":52},"2025-04-02",{"date":517,"type":52},"2018-05-29",{"date":519,"type":21},"2029-05-29",{"name":521,"class":106},"Institut du Cancer de Montpellier - Val d'Aurelle",{"id":523,"slug":524,"hasResults":11,"nctId":525,"briefTitle":526,"officialTitle":527,"acronym":4,"eligibilityCriteria":528,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":529,"targetDuration":4,"studyType":72,"phases":4,"briefSummary":531,"conditions":532,"keywords":533,"overallStatus":184,"whyStopped":4,"lastUpdateSubmitDate":537,"lastUpdatePostDateStruct":538,"startDateStruct":540,"completionDateStruct":541,"leadSponsor":543,"locationsCount":84},"100575444","sers-based-serum-molecular-spectral-screening-for-hematogenous-metastasis-100575444","NCT06772363","SERS-Based Serum Molecular Spectral Screening for Hematogenous Metastasis","SERS-Based Serum Molecular Spectral Screening for Hematogenous Metastasis vs. Non-Metastasis in Non-Small Cell Lung Cancer: A Multicenter, Open-Label, Double-Blind, Independent Data Analysis Clinical Trial","Inclusion Criteria:\n\n1. Participants with Lung cancer meeting the criteria of TNM (Ninth Edition);\n2. Participants are willing to participate in this study and follow the research plan;\n3. Participants or legally authorized representatives can give written informed consent approved by the Ethics Review Committee that manages the website;\n\nExclusion Criteria:\n\n1. Participants with concomitant other malignant tumors;\n2. Participants with missing baseline clinical data;\n3. Participants with severe underlying lung diseases (such as bronchiectasis, bronchial asthma or COPD, etc.), or those with a history of occupational or environmental exposure to dust, mines or asbestos;\n4. Participants who do not cooperate or refuse to participate in clinical trials at a later stage.",{"count":530,"type":21},200,"Although modern medicine has made significant progress in the diagnosis and treatment of lung cancer, most patients are diagnosed at locally advanced stage or with distant metastases, especially in the late stages where the cancer has spread to other organs through hematogenous metastasis. This not only significantly the survival rate of patients but also increases the complexity and difficulty of treatment. Hematogenous metastasis plays an important role in the clinical progression of lung cancer, its complex biological processes pose a huge challenge for clinical management. Early detection of hematogenous metastasis is difficult, and traditional imaging methods have limited sensitivity in detecting small metastatic lesions. The emerging technology of circulating tumor cells (CTCs) has been limited in clinical application due to its high detection costs and technical requirements. Therefore researching and developing high-sensitivity, high-specificity, simple, easy-to-popularize, and low-cost technologies to predict the risk of hematogenous metastasis lung cancer is crucial for early diagnosis and more precise treatment. Raman spectroscopy (RS), a non-invasive and highly specific molecular detection technology, can detect in biomolecules such as proteins, nucleic acids, lipids, and sugars related to tumor metabolism in biological samples at the molecular level. Surface-enhanced R spectroscopy (SERS), developed based on this technology, is one of the feasible methods for high-sensitivity biomolecular analysis. Although SERS technology has shown diagnostic results in numerous preclinical studies of various tumors, it is limited by small sample sizes and lacks external validation. Therefore, clinical studies on the diagnosis of tumors Raman spectroscopy are needed, with the following requirements: 1. Objective, rapid, and practical Raman spectroscopy data processing methods are needed, and and deep learning methods may be the best classification methods; 2. Multicenter, large-sample clinical samples are needed to train deep learning diagnostic models, and real-world performance should be validated through external data from prospective studies. In previous study, the investigators collected serum Raman spectroscopy data from a cohort of 23 patients with lung malignancies and developed an intelligent Raman diagnostic system for hematogenous metastasis in non-small cell lung cancer (NSCLC) based on learning models, with an accuracy rate of 95%. To obtain the highest level of clinical evidence and truly achieve clinical translation, this prospective, multicenter clinical aims to validate the use of this intelligent diagnostic system for early diagnosis of hematogenous metastasis in NSCLC.",[31],[534,47,535,536],"SERS","Raman","diagnostic model","2025-03-26",{"date":539,"type":52},"2025-03-31",{"date":75,"type":21},{"date":542,"type":21},"2026-06-01",{"name":544,"class":106},"Fuzhou General Hospital",{"id":546,"slug":547,"hasResults":11,"nctId":548,"briefTitle":549,"officialTitle":550,"acronym":551,"eligibilityCriteria":552,"healthyVolunteers":67,"sex":16,"minAge":553,"maxAge":4,"enrollmentInfo":554,"targetDuration":4,"studyType":72,"phases":4,"briefSummary":556,"conditions":557,"keywords":578,"overallStatus":48,"whyStopped":4,"lastUpdateSubmitDate":584,"lastUpdatePostDateStruct":585,"startDateStruct":587,"completionDateStruct":589,"leadSponsor":591,"locationsCount":84},"100361552","empower-1-a-multi-site-clinical-cohort-research-study-to-reduce-health-inequality-100361552","NCT03987633","EMPOWER-1: A Multi-site Clinical Cohort Research Study to Reduce Health Inequality","EMPOWER-1: A Multi-site Clinical Cohort Study to Reduce Health Inequality: Identifying Ethnic Disparities in Treatment Failures for Medicines Prescribed to Treat Diseases That Cause Significant Mortality and Morbidity in the UK Population","EMPOWER","Inclusion Criteria:\n\n1. Patients or their relative\u002Ffamily member is diagnosed with the illness being investigated by this study.\n2. All NHS patients that are associated with a participating study site, but do not fall under the first bullet point above, may participate with a view that they may potentially contribute to a case control population in the research study.\n3. Subjects agree to:\n\n   1. Gift biological samples, i.e. saliva. Where practical, blood or other biological samples may be voluntarily provided by the patient.\n   2. Provide Consent for access to medical records.\n   3. Complete disease specific, quality of life, and study associated questionnaires.\n\nExclusion Criteria:\n\n1. Patient does not provide a valid consent for study participation.\n2. Patient is not registered with the NHS for care.\n3. Patient lacking capacity, who does not have an illness that is being specifically investigated by this clinical research study.\n4. Person lacks capacity and where the personal consultee has not advised that the Person may enrol, in accordance with the Mental Health Act 2005.","6 Years",{"count":555,"type":21},200000,"Health inequality and genetic disparity are a significant issue in the United Kingdom (UK).\n\nThis study focuses on diseases that are associated with significant morbidity and mortality in the UK, and specifically examines the extent and basis of treatment failure in different patient populations.\n\nThe vast majority of drug registration clinical trials have under-representation of ethnic minority populations. In addition, the wider Caucasian populations have reasonably different clinical characteristics to the population that participated in the drug licencing clinical trials. A consequence of this is that drugs are licensed for use in real-world general patient populations where the clinical trial results are simply not statistically significant to specifically demonstrate efficacy or safety in populations that were either absent or under-represented in the drug registration clinical trials. When these facts are considered alongside data that supports significant under-reporting of adverse events in the real-world setting within the UK (and globally, e.g the USA and Europe), it highlights that pharmacovigilance systems are unable to capture drug effectiveness and safety data in a manner that can reasonably assure appropriate prescribing in the wider patient populations.\n\nThis large real-world research study aims to identify whether commonly prescribed drugs are effective in treating illnesses that cause significant poor health and death in the different patient populations that represent the UK.\n\nThe goal of this study is to generate large quantitative data-sets that may inform clinical practice to reduce the existing health inequality and genetic disparity in the UK.",[558,559,560,561,562,563,564,565,566,567,335,568,569,570,571,572,573,574,575,576,577,31],"Atrial Fibrillation","Coronary Heart Disease","Cardiovascular Diseases","Heart Failure","Hypertension","Peripheral Arterial Disease","Stroke, Ischemic","Asthma","Chronic Obstructive Pulmonary Disease","Obesity","Chronic Kidney Diseases","Diabetes Mellitus","Dementia","Depression","Epilepsy","Mental Health Disorder","Rheumatoid Arthritis","Blood Pressure","Breast Cancer Risk","Prostate Cancer",[579,580,581,582,583],"genetic disparity","health inequality","genetics","health outcomes","equality","2025-03-05",{"date":586,"type":52},"2025-03-10",{"date":588,"type":52},"2020-02-01",{"date":590,"type":21},"2030-02-01",{"name":592,"class":106},"Future Genetics Limited",{"id":594,"slug":595,"hasResults":11,"nctId":596,"briefTitle":597,"officialTitle":598,"acronym":599,"eligibilityCriteria":600,"healthyVolunteers":67,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":601,"targetDuration":4,"studyType":72,"phases":4,"briefSummary":603,"conditions":604,"keywords":609,"overallStatus":184,"whyStopped":4,"lastUpdateSubmitDate":618,"lastUpdatePostDateStruct":619,"startDateStruct":621,"completionDateStruct":623,"leadSponsor":625,"locationsCount":84},"100570799","vocorder-device-validation-in-clinical-settings---continuous-monitoring-of-individuals-vocorder-clinical-validation-vcv-100570799","NCT06711939","Vocorder Device Validation in Clinical Settings - Continuous Monitoring of Individuals (Vocorder Clinical Validation-VCV)","Vocorder Device Validation in Clinical Settings - Continuous Monitoring of Individuals (Vocorder Clinical Validation-VCV). This Clinical Study Will Explore the Correlation Analysis Between Volatile Organic Compounds (VOC) Profiles in Breath As Detected by the VOCORDER Breath Analyser and Electronic Medical Data As Collected by Medical Professionals. the Obtained Results Are Expected to Be Significant in Refining the Technology of Breath Analysis in the VOCORDER Breath Analyser for the Early Detection of Diseases of Interest.","VCV","Inclusion Criteria:\n\n* Patients aged 18-75 years of both genders, selected according to the following inclusion criteria:\n\n  1. Patients\\>18 years of age of both genders\n  2. They must be able to communicate and understand the information given to them by the MITERA staff.\n  3. Suffer from the disease under investigation.\n  4. The disease must be at the earliest possible stage, i.e., the patients must not yet have started treatment.\n  5. Patients should have no other serious comorbidities that affect the derived measurements. Patients will be selected in collaboration with the clinicians responsible for the treatment and\u002For hospitalisation of patients with the diseases under investigation.\n\n     Criteria 1, 2, and 3 are mandatory for enrollment in the study. For the enrollment of the patients in the study specific documentation of the disease should be available to the project team as following:\n* Healthy controls of both sexes, aged between 20 and 75 years, who do not suffer from the diseases under investigation will be selected for participation in the study at the same time as the patients.\n\nExclusion Criteria:\n\n* Lack of signed consent\n* Lack of co-operation due to any reason\n* Failure to follow the recommendations on the requirements prior to the breath sampling procedure\n* Inability to provide a reliable breath sample\n* Any treatment, specific diet, surgery, or other intervention having been initiated between obtaining samples for breath VOCs.",{"count":602,"type":21},515,"This is performed under Vocorder project that is Co-Funded by the European Union. (Grant Agreement 101115442 VOCORDER HORIZON EIC-2022-PATHFINDERCHALLENGE-01). The projects has 9 work packages (one dedicated to the clinical study) and 12 partners (collaborators). MITERA Hospital serves as the project Coordinator as well as the leader of the clinical study.\n\nVOCORDER aims to create a paradigm shift in healthcare monitoring by developing a portable device for continuous assessment of health through breath analysis.\n\nOur mission is to make health monitoring seamless and non-intrusive, empowering individuals and healthcare professionals with real-time data and proactive health management.\n\nOur vision is to make continuous health monitoring a part of everyday life, helping in early disease detection and management. We are on a mission to create accessible, easy-to-use technology that integrates seamlessly into daily routines.\n\nOur objective is to create a tool designed for the discreet and continuous monitoring of human health. This involves the development and implementation of a system that can consistently assess, process, and analyze human breath. The key aim is to detect early indicators of diseases, thereby facilitating timely and proactive healthcare interventions.\n\nStrategic objectives\n\n1. Provide a solution for easy-to-use breath analysis able to monitor the health of any individual at any setting.\n2. Develop and demonstrate the beyond state-of-the-art technologies needed to implement the VOCORDER breath analysis apparatus.\n3. Develop a health monitoring apparatus people can easily integrate into their everyday life.\n\nScientific and technological Objectives\n\n1. Demonstration of QCLs and ICLs monolithically integrated arrays.\n2. Integrate QCLs\u002FICLs arrays with MPLC components for beam combing and providing high quality beam profile.\n3. Implement a detector-less sensing scheme.\n4. Enable AI-based breath analysis for the identification of health conditions.\n5. Implement clinical studies of VOCORDER.",[605,606,337,31,607,608],"Cancer of the Breast","Cancer of Stomach","Kidney Insufficiency","Pneumonia",[610,611,612,613,154,614,615,616,617],"VOC","breath analysis","organ insufficiency","infections","Gastric and colon cancer","Breast cancer","Kidney insufficiency","Infections - Pneumonia","2024-11-27",{"date":620,"type":52},"2024-12-02",{"date":622,"type":21},"2024-12-09",{"date":624,"type":21},"2026-12-31",{"name":626,"class":106},"Mitera Hospital",{"id":628,"slug":629,"hasResults":11,"nctId":630,"briefTitle":631,"officialTitle":632,"acronym":4,"eligibilityCriteria":633,"healthyVolunteers":67,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":634,"targetDuration":4,"studyType":22,"phases":636,"briefSummary":637,"conditions":638,"keywords":643,"overallStatus":48,"whyStopped":4,"lastUpdateSubmitDate":647,"lastUpdatePostDateStruct":648,"startDateStruct":650,"completionDateStruct":651,"leadSponsor":653,"locationsCount":84},"100564723","ai-assisted-non-contrast-ct-for-multi-cancer-screening-100564723","NCT06632886","AI-Assisted Non-Contrast CT for Multi-Cancer Screening","A Prospective Cohort Study Evaluating the Utility of Artificial Intelligence-Assisted Non-Contrast Computed Tomography for Multi-Cancer Screening in Asymptomatic Individuals Undergoing Routine Health Examinations","Inclusion Criteria:\n\n1. Subject is able and willing to provide informed consent and sign an informed consent form.\n2. Subject has undergone an abdominal or chest non-contrast CT scan.\n\nExclusion Criteria:\n\n1. Subject has been diagnosed with one of the following cancers within the last five years: lung, liver, stomach, colon, esophageal, pancreatic, or breast cancer;\n2. Subject has any medical condition that contraindicates high-resolution MRI\u002FCT\u002FEndoscopy;\n3. Subject cannot be followed up or is participating in other clinical trials.",{"count":635,"type":21},1000000,[149],"Cancer poses a major public health challenge in China. Early detection can improve treatment outcomes and survival rates. In this study, we will conduct a large-scale, prospective, multi-center cohort study to evaluate the utility of AI-assisted non-contrast CT for multi-cancer screening.\n\nThe study aims to enroll 1 million asymptomatic participants undergoing routine health examinations, using an AI imaging model based on non-contrast CT to detect seven cancers such as lung, liver, gastric, colorectal, esophageal, pancreatic, and breast cancers. Positive cases will be required to be referred to Shanghai Changhai Hospital for further imaging and care based on National Comprehensive Cancer Network (NCCN) and American College of Radiology (ACR) guidelines. The goal is to assess the AI model's diagnostic performance for seven cancer types, especially for early-stage, resectable tumors.",[31,639,640,641,642,488,121],"Liver Cancer","Gastric Cancers","Colorectal, Cancer","Esophageal Cancer",[644,645,646,335],"Screening","Early Diagnosis","Artificial Intelligence","2024-10-07",{"date":649,"type":52},"2024-10-09",{"date":647,"type":21},{"date":652,"type":21},"2027-10-07",{"name":654,"class":106},"Guo ShiWei"]